5.52MMarket Cap-96P/E (TTM)
0.3018High0.2743Low46.86KVolume0.3018Open0.2731Pre Close13.32KTurnover0.32%Turnover RatioLossP/E (Static)19.52MShares2.907752wk High-0.60P/B4.12MFloat Cap0.270152wk Low--Dividend TTM14.54MShs Float1457.9988Historical High--Div YieldTTM10.07%Amplitude0.2701Historical Low0.2840Avg Price1Lot Size
Aptose Biosciences Stock Forum
Aptose Initiates TUSCANY Phase 1/2 Study for Newly Diagnosed AML Patients to Receive Tuspetinib-based Triplet Therapy
2 minutes ago, 4:30 AM PST
Via GlobeNewswire
APTO
Share
• TUSCANY study is open to enroll patients to receive TUS+VEN+AZA triplet at select US sites
• Favorable safety and broad clinical activity make tuspetinib an ideal agent to combine with venetoclax and azacitidine to potentially address larger AML populations
• Study execution update is ...
patience needed here.
No comment yet